inlyta
NICE gives initial ‘no’ to NHS England for kidney cancer drug
February 18, 2020Manufacturing and Production NHS England, NICE, clinical trials, inlyta, keytruda
The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment …
Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer
October 29, 2019Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer
April 23, 2019Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma
MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …
Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer
February 18, 2019Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …
MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma
February 18, 2019Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma
Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …
Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma
February 12, 2019Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma
New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …
MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer
October 19, 2018Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma
MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …
Pfizer shuts down kidney cancer drug trial due to “futility”
April 11, 2018Research and Development Cancer, Kidney cancer, Pfizer, inlyta, pharma
Pfizer has revealed that it has shut down a trial of its vascular endothelial growth factor (VEGF) inhibitor Inlyta (axitinib) …
Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug
April 6, 2016Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal
The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
Pfizer gets early approval for breast cancer drug
February 4, 2015Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib
The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
NICE U-turn on Pfizer drug Inlyta
March 5, 2014Research and Development, Sales and Marketing Kidney cancer, NHS, NICE, Pfizer, axitinib, inlyta
NICE has recommended that Pfizer’s kidney cancer drug Inlyta should be used for some patients in England, following a similar …
Torisel fails in head-to-head study with Nexavar
May 16, 2012Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc
Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial. The Phase III study was …
Major new drugs for 2012
March 9, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta
Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …
